Immunotherapy trials in mesothelioma promising results, but don't stop here
In the past few years, several studies have addressed the possibility of using immunotherapies to treat patients with mesothelioma. Herein, we discuss two recent trials, one testing the immune checkpoint inhibitor nivolumab and the other testing a mesothelin directed therapeutic vaccine, and reflect on the advances and challenges remaining in this research area.
Nature Reviews Clinical Oncology